文献速递骨质疏松与代谢性骨病骨肿瘤

免疫检查点抑制剂治疗后的骨密度变化:病例系列分析启示

Bone mineral density changes following immune checkpoint inhibitor therapy: insights from a case series analysis.
PubMed 文献 · Osteoporos Int · 2025-08-10

该回顾性病例系列分析纳入15例肿瘤患者,在免疫检查点抑制剂(ICI)治疗前后用双能X线吸收法(DXA)评估骨密度(BMD)变化,中位随访12个月。基线骨质疏松患者股骨和腰椎BMD分别降低6%和17.30%,而基线骨量正常或骨量减少患者无显著变化,随访期间未发生骨质疏松性骨折。

要点

  • 基线骨质疏松患者ICI治疗后股骨BMD降低6%、腰椎BMD降低17.30%。
  • 基线骨量正常或骨量减少患者股骨和腰椎BMD无显著变化。
  • 中位随访12个月内未观察到骨质疏松性骨折。

核心结论

  • ICI对肿瘤患者骨代谢的影响仍未明确;本队列中基线骨量正常和骨量减少患者在中位12个月随访后BMD无显著变化,而基线骨质疏松患者在股骨和腰椎两个部位受影响最大。

研究设计与样本

  • 回顾性分析15例肿瘤患者ICI治疗前后DXA测量的BMD变化百分比及骨质疏松性骨折发生情况,中位随访12个月。

主要发现

  • 基线骨量正常患者股骨和腰椎BMD中位降低分别为0.15%和0.10%。
  • 基线骨量减少患者股骨BMD无变化,腰椎BMD中位降低0.07%。
  • 基线骨质疏松患者股骨和腰椎BMD分别降低6%和17.30%。
  • 中位随访12个月期间未发生骨质疏松性骨折。

局限性

  • 原文结论指出需要更大规模的前瞻性研究来重复本研究发现并明确这些药物对骨骼的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Brief rationale: The use of ICIs is increasing rapidly. Limited studies support potential effects on bone health. MAIN RESULT: Osteoporotic patients demonstrated a 6% and 17% reduction in femoral and lumbar spine BMD, respectively. Paper significance: This is a real-world data record of the effect of one-year ICI treatment on skeletal health. PURPOSE: Immune checkpoint inhibitors (ICIs) are used as a treatment for various malignancies, resulting in the occurrence of a plethora of immune-related adverse events (irAEs). An increasing interest has emerged on the possible effects of these drugs on the skeleton, predominantly osteoporotic fractures, although bone health studies are scarce. METHODS: Our study analyzed retrospectively the percentage of the alteration of the bone mineral density (BMD) evaluated by Dual Energy X-Ray Absorptiometry (DXA) scan in 15 oncological patients before and after the administration of ICIs, as well as the occurrence of osteoporotic fractures, within a median follow-up period of 12 months. RESULTS: Patients with normal baseline BMD presented a median femoral and lumbar BMD reduction of 0.15% and 0.10%, respectively. Patients with a baseline BMD in favor of osteopenia exhibited no alterations in the femoral BMD and a median 0.07% reduction in the lumbar BMD. Patients with baseline osteoporosis demonstrated a femoral and lumbar BMD reduction of 6% and 17.30%, respectively. No osteoporotic fracture was demonstrated during the median follow-up period of 12 months. CONCLUSIONS: ICIs effect on bone metabolism of oncological patients remains undefined. In our cohort, patients with normal BMD and osteopenia did not present a significant change in the BMD after a median follow-up of 12 months. However, patients with baseline osteoporosis were the most affected in both sites. Larger prospective studies are needed to replicate our findings and to define the impact of these drugs on the skeleton.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Siampanopoulou V, Ziogas DC, Lyrarakis G, et al. Bone mineral density changes following immune checkpoint inhibitor therapy: insights from a case series analysis. Osteoporos Int. 2025. PMID: 40783905. doi:10.1007/s00198-025-07647-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。